Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2/3 study of ELA026

Next Previous
Trial Profile

Phase 2/3 study of ELA026

Status: Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELA 026 (Primary)
  • Indications Haemophagocytic lymphohistiocytosis; Immunological disorders
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 09 Dec 2024 According to an Electra Therapeutics Inc media release, the company have a clear path forward based on recent alignment with the US FDA on the pivotal study design and are moving towards initiating a global Phase 2/3 study in 2025 to address the significant disease burden in sHLH.
  • 16 Dec 2022 New trial record
  • 12 Dec 2022 According to an Electra Therapeutics media release, phase 1b study will identify the dose for Phase 2/3 testing.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top